Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELEMENT: elacestrant added to olaparib in HR-positive/HER2-negative gBRCA-mutated advanced breast cancer
2023-504925-38-00Phase 2Authorised
- Sponsor
- GBG Forschungs
- Start
- Mar 2024
- Modality
- Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in breast cancer comparing Elacestrant + olaparib with Olaparib standard-of-care (2 arms). Primary endpoint: Progression-free survival. Planned start Mar 2024; status: authorised.
02
Drugs
elacestrantolaparib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2023-504925-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504925-38-00.